Related Experiment Video
Updated: Jul 19, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Drug-induced liver disease
1Division of Gastroenterology, Section of Hepatology, Georgetown University Medical Center, Washington, District of Columbia 20007, USA.
Current Opinion in Gastroenterology
|October 13, 2006
Summary
This review covers drug withdrawals and new cases of drug-induced liver injury (DILI). It also discusses acetaminophen toxicity treatments and preventing DILI in patients with chronic diseases.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Toxicology
Background:
- Drug-induced liver disease (DILI) remains a significant clinical challenge.
- Understanding new agents and established drugs causing DILI is crucial for patient safety.
- The year 2000 saw new reports and classifications of drug-induced liver injury.
Purpose of the Study:
- To provide a comprehensive review of DILI in the year 2000.
- To update knowledge on drug withdrawals and newly identified hepatotoxic agents.
- To discuss advancements in acetaminophen toxicity management and DILI prevention.
Main Methods:
- Literature review of drug withdrawals and DILI reports from the year 2000.
- Analysis of newly described agents causing DILI.
- Review of established agents with new DILI reports.
- Examination of treatment strategies for acetaminophen toxicity.
- Assessment of DILI prevention in patients with chronic diseases.
Main Results:
- Identification of agents newly reported to cause DILI.
- Documentation of DILI from established agents in the year 2000.
- Updates on the classification of drug-induced liver injury.
- New insights into the treatment of acetaminophen toxicity.
- Considerations for preventing DILI in patients with comorbidities.
Conclusions:
- Ongoing vigilance is required for identifying and managing DILI.
- Newer agents and established drugs necessitate continuous monitoring for hepatotoxicity.
- Effective management of acetaminophen toxicity and DILI prevention strategies are vital.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...